Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders

Re-treatment of Patients With Chronic Hepatitis C Who Do Not Respond to Peginterferon-α2b

(2013) Donald M. Jensen   ANNALS OF INTERNAL MEDICINE

1376 THE ASPIRE TRIAL: TMC435 IN TREATMENT-EXPERIENCED PATIENTS WITH GENOTYPE-1 HCV INFECTION WHO HAVE FAILED PREVIOUS PEGIFN/RBV TREATMENT

(2011) S. Zeuzem et al.   JOURNAL OF HEPATOLOGY

1356 QUADRUPLE THERAPY WITH BMS-790052, BMS-650032 AND PEG-IFN/RBV FOR 24 WEEKS RESULTS IN 100% SVR12 IN HCV GENOTYPE 1 NULL RESPONDERS

(2011) A. Lok et al.   JOURNAL OF HEPATOLOGY

1195 BMS-650032, AN NS3 INHIBITOR, IN COMBINATION WITH PEGINTERFERON ALPHA-2A AND RIBAVIRIN IN TREATMENT-NAIVE SUBJECTS WITH GENOTYPE 1 CHRONIC HEPATITIS C INFECTION

(2011) J.-P. Bronowicki et al.   JOURNAL OF HEPATOLOGY

Influence of HCV genotype 1 subtypes on the virus response to PEG interferon alpha-2a plus ribavirin therapy

(2011) F. Nicot et al.   JOURNAL OF MEDICAL VIROLOGY

A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt

(2011) William Sievert et al.   LIVER INTERNATIONAL

The global health burden of hepatitis C virus infection

(2011) Francesco Negro et al.   LIVER INTERNATIONAL

A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel

(2011) Markus Cornberg et al.   LIVER INTERNATIONAL

Boceprevir for Untreated Chronic HCV Genotype 1 Infection

(2011) Fred Poordad et al.   NEW ENGLAND JOURNAL OF MEDICINE

Telaprevir for Retreatment of HCV Infection

(2011) Stefan Zeuzem et al.   NEW ENGLAND JOURNAL OF MEDICINE

Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection

(2011) Ira M. Jacobson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Resistance Analysis of the Hepatitis C Virus NS5A Inhibitor BMS-790052 in an In Vitro Replicon System

(2010) R. A. Fridell et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Interleukin-28B Polymorphism Improves Viral Kinetics and Is the Strongest Pretreatment Predictor of Sustained Virologic Response in Genotype 1 Hepatitis C Virus

(2010) Alexander J. Thompson et al.   GASTROENTEROLOGY

761 IDENTIFICATION AND PRECLINICAL PROFILE OF THE NOVEL HCV NS3 PROTEASE INHIBITOR BMS-650032

(2010) F. McPhee   JOURNAL OF HEPATOLOGY

Elimination of hepatitis C virus by short term NS3-4A and NS5B inhibitor combination therapy in human hepatocyte chimeric mice

(2010) Eiji Ohara et al.   JOURNAL OF HEPATOLOGY

Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial

(2010) Edward J Gane et al.   LANCET

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect

(2010) Min Gao et al.   NATURE

Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding

(2010) K. P. Romano et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

New Therapies for Hepatitis C Virus Infection

(2009) Vincent Soriano et al.   CLINICAL INFECTIOUS DISEASES

Peginterferon alfa-2b and Ribavirin: Effective in Patients With Hepatitis C Who Failed Interferon alfa/Ribavirin Therapy

(2009) Thierry Poynard et al.   GASTROENTEROLOGY

Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients

(2009) Simone Susser et al.   HEPATOLOGY

Influence of the HCV subtype on the virological response to pegylated interferon and ribavirin therapy

(2009) Florence Legrand-Abravanel et al.   JOURNAL OF MEDICAL VIROLOGY

Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection

(2009) John G. McHutchison et al.   NEW ENGLAND JOURNAL OF MEDICINE

Diagnosis, management, and treatment of hepatitis C: An update

(2008) Marc G. Ghany et al.   HEPATOLOGY